Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

NRX Pharmaceuticals (NRXP) Enterprise Value (2024 - 2026)

NRX Pharmaceuticals (NRXP) has disclosed Enterprise Value for 2 consecutive years, with -$7.8 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 440.33% to -$7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.8 million through Dec 2025, down 440.33% year-over-year, with the annual reading at -$7.8 million for FY2025, 440.33% down from the prior year.
  • Enterprise Value for Q4 2025 was -$7.8 million at NRX Pharmaceuticals, down from -$7.2 million in the prior quarter.
  • The five-year high for Enterprise Value was -$1.3 million in Q1 2024, with the low at -$7.8 million in Q4 2025.